Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002721 · ClinicalTrials.gov registry record · Phase 1
Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
A Phase 1 study, sponsored by University of New Mexico.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00002721 is a Phase 1 study that has completed, run by University of New Mexico. The registered enrollment target is 18 participants.
The verdict
NCT00002721, a Phase 1 study, has completed, sponsored by University of New Mexico.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in treating patients with metastatic recurrent prostate cancer that does not respond to hormone therapy.
Interventions
- DRUG doxorubicin hydrochloride
- DRUG estramustine phosphate sodium
- PROCEDURE drug resistance inhibition treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 1995-03 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002721
The ClinicalTrials.gov registry entry for NCT00002721 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of New Mexico, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which doxorubicin hydrochloride is the first listed.
NCT00002721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002721 about?
NCT00002721 is a clinical study titled "Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in treating patients with metastatic rec...
What is the current status of trial NCT00002721?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 1995-03. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00002721?
The interventions under investigation include: doxorubicin hydrochloride (DRUG), estramustine phosphate sodium (DRUG), drug resistance inhibition treatment (PROCEDURE).
Who is sponsoring clinical trial NCT00002721?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.